Novo Nordisk Statistics

Total Valuation

Novo Nordisk has a market cap or net worth of EUR 243.92 billion. The enterprise value is 254.16 billion.

Market Cap	243.92B
Enterprise Value	254.16B

Important Dates

The next estimated earnings date is Wednesday, May 7, 2025.

Earnings Date	May 7, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.71%
Shares Change (QoQ)	-0.11%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.18B

Valuation Ratios

The trailing PE ratio is 18.01.

PE Ratio	18.01
Forward PE	n/a
PS Ratio	6.26
PB Ratio	12.68
P/TBV Ratio	56.15
P/FCF Ratio	24.65
P/OCF Ratio	15.04
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.80, with an EV/FCF ratio of 25.68.

EV / Earnings	18.77
EV / Sales	6.53
EV / EBITDA	12.80
EV / EBIT	13.56
EV / FCF	25.68

Financial Position

The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.72.

Current Ratio	0.74
Quick Ratio	0.52
Debt / Equity	0.72
Debt / EBITDA	0.69
Debt / FCF	1.39
Interest Coverage	85.29

Financial Efficiency

Return on equity (ROE) is 80.78% and return on invested capital (ROIC) is 46.03%.

Return on Equity (ROE)	80.78%
Return on Assets (ROA)	22.41%
Return on Invested Capital (ROIC)	46.03%
Return on Capital Employed (ROCE)	56.34%
Revenue Per Employee	506,855
Profits Per Employee	176,260
Employee Count	77,349
Asset Turnover	0.74
Inventory Turnover	1.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -53.14% in the last 52 weeks. The beta is 0.25, so Novo Nordisk's price volatility has been lower than the market average.

Beta (5Y)	0.25
52-Week Price Change	-53.14%
50-Day Moving Average	69.80
200-Day Moving Average	96.24
Relative Strength Index (RSI)	37.33
Average Volume (20 Days)	274,885

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novo Nordisk had revenue of EUR 38.94 billion and earned 13.54 billion in profits. Earnings per share was 3.03.

Revenue	38.94B
Gross Profit	33.10B
Operating Income	18.76B
Pretax Income	17.05B
Net Income	13.54B
EBITDA	19.67B
EBIT	18.76B
Earnings Per Share (EPS)	3.03

Full Income Statement

Balance Sheet

The company has 3.53 billion in cash and 13.78 billion in debt, giving a net cash position of -10.25 billion.

Cash & Cash Equivalents	3.53B
Total Debt	13.78B
Net Cash	-10.25B
Net Cash Per Share	n/a
Equity (Book Value)	19.24B
Book Value Per Share	4.33
Working Capital	-7.59B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 16.22 billion and capital expenditures -6.32 billion, giving a free cash flow of 9.90 billion.

Operating Cash Flow	16.22B
Capital Expenditures	-6.32B
Free Cash Flow	9.90B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 85.00%, with operating and profit margins of 48.17% and 34.78%.

Gross Margin	85.00%
Operating Margin	48.17%
Pretax Margin	43.80%
Profit Margin	34.78%
EBITDA Margin	50.51%
EBIT Margin	48.17%
FCF Margin	25.41%

Dividends & Yields

This stock pays an annual dividend of 1.53, which amounts to a dividend yield of 2.96%.

Dividend Per Share	1.53
Dividend Yield	2.96%
Dividend Growth (YoY)	21.20%
Years of Dividend Growth	5
Payout Ratio	43.71%
Buyback Yield	0.71%
Shareholder Yield	3.66%
Earnings Yield	5.55%
FCF Yield	4.06%

Dividend Details

Stock Splits

The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.

Last Split Date	Sep 13, 2023
Split Type	Forward
Split Ratio	2

Scores

Novo Nordisk has an Altman Z-Score of 8.94.

Altman Z-Score	8.94
Piotroski F-Score	n/a